Should Insmed’s (INSM) EMA Nod for BRINSUPRI Prompt a Fresh Look at Its Growth Prospects?

Insmed's BRINSUPRI received a positive opinion from the European Medicines Agency’s CHMP on October 17, 2025, recommending its approval for non-cystic fibrosis bronchiectasis (NCFB), which would make it the first authorized therapy for the condition in the EU. This European regulatory momentum, following the August 2025 FDA approval in the U.S., significantly strengthens Insmed's investment narrative and potential for multi-region commercial launches. However, critical challenges related to market access and reimbursement, particularly in the U.S., persist and will heavily influence the realization of the company's ambitious revenue and profit projections for 2028.

Analysis

Insmed (INSM) received a positive opinion from the European Medicines Agency’s CHMP on October 17, 2025, recommending approval of BRINSUPRI for non-cystic fibrosis bronchiectasis (NCFB). This development is significant as BRINSUPRI would become the first authorized therapy for NCFB in the EU, following its August 2025 FDA approval in the U.S.

This dual regulatory momentum strongly reinforces Insmed's investment narrative and its potential for multi-regional commercial launches, mitigating near-term European approval risk. The company's narrative projects substantial growth, targeting $1.9 billion in revenue and $293.8 million in earnings by 2028, necessitating a 72.0% yearly revenue growth rate.

Despite regulatory successes, the most pressing short-term factor remains the timing and commercial success of the U.S. BRINSUPRI launch. Critical risks tied to market access and reimbursement, particularly in the U.S., represent key variables that could significantly influence future revenue and profit expectations, with payer pushback noted as a concern.

Simply Wall St estimates a fair value of $172.59 for Insmed, representing a 4% upside, based on these projections. However, the wide range of community-submitted fair value estimates, extending up to $21,337.07, underscores the highly speculative nature and diverse perspectives on how market access will ultimately impact BRINSUPRI's uptake and Insmed's long-term value.

Key Decisions for Investors

• Monitor closely the commercial launch trajectory of BRINSUPRI in the U.S., specifically focusing on market access, reimbursement rates, and patient uptake, as these are critical for validating Insmed's ambitious 2028 financial projections.
• Evaluate Insmed's ability to navigate payer reimbursement challenges and potential pushback in the U.S. market, which remains a significant variable for future revenue and profit realization despite positive regulatory approvals.
• Given the speculative nature highlighted by the wide range of fair value estimates, investors should conduct thorough due diligence on Insmed's execution capabilities and risk management strategies related to multi-regional commercialization.